Objective To compare the safety and efficacy of fertility-sparing surgery in patients with ovarian borderline tumors (BOT). Methods A total of 121 BOT patients undergoing fertility-sparing surgery between January 2010 and October 2022 were retrospectively analyzed.The univariate analysis,multivariate analysis,and survival curves were employed to evaluate the clinicopathological and surgical variables and fertility. Results The 121 BOT patients included in this study showed the 5-year recurrence-free survival (RFS) rate of 65.8% and the recurrence rate of 30.5%.A total of 53 patients attempted to conceive and 40 (33.06%) of the patients achieved successful pregnancy.Different methods of fertility-sparing surgery did not affect the tumor recurrence rate,RFS,or pregnancy rate.The multivariate analysis indicated that the International Federation of Gynecology and Obstetrics (FIGO) stage ≥Ⅱ was an independent risk factor affecting both postoperative recurrence and RFS (P=0.011,OR=6.504,95%CI=1.534-27.58;P=0.033,HR=2.589,95%CI=1.082-6.194) in BOT patients.Tissue type (mucinous) was negatively correlated with the risk of recurrence after fertility-sparing surgery (P=0.011,OR=0.270,95%CI=0.099-0.739).The two unilateral surgical methods showed differences in the amount of intraoperative bleeding (P=0.010),postoperative hospital stay (P=0.001),duration of antibiotic use (P=0.002),and tumor rupture rate (P=0.030),which were not significantly different between the two bilateral surgical methods. Conclusions For young patients with fertility requirements,fertility-sparing surgery is safe and effective.After a comprehensive assessment of clinicopathological factors,unilateral cystectomy and bilateral cystectomy may be recommended as the preferred choice of treatment.For the patients with advanced FIGO stages who strongly prefer fertility sparing,fertility-sparing surgery can be performed with fully informed consent,and these patients should attempt to achieve pregnancy as soon as possible after the surgery.
目的 比较不同保留生育功能手术方式对卵巢交界性肿瘤(BOT)患者的肿瘤预后及生育力的安全性和有效性。方法 回顾性分析2010年1月至2022年10月121例行保留生育功能手术的BOT患者,采用单因素、多因素分析及生存曲线评估临床病理、手术方式及生育情况。结果 121例BOT患者5年无复发生存期(RFS)率为65.8%,复发率为30.5%,53例患者尝试妊娠,40例(33.06%)成功妊娠。保留生育功能手术的不同手术方式对患者的肿瘤复发、RFS和妊娠率无影响。多因素分析中,国际妇产科联盟分期≥Ⅱ期是同时影响BOT患者术后复发及RFS的独立危险因素(P=0.011,OR=6.504,95% CI=1.534~27.580;P=0.033,HR=2.589,95% CI=1.082~6.194),组织类型(黏液性)与保留生育功能手术术后的复发风险呈负相关性(P=0.011,OR=0.270,95% CI=0.099~0.739)。单侧BOT的两种手术方式手术出血量(P=0.010)、术后住院时间(P=0.001)、抗生素使用时间(P=0.002)、瘤体破裂(P=0.030)差异均有统计学意义,而双侧BOT两组手术方式差异均无统计学意义(P均>0.05)。结论 对于年轻且有生育要求的BOT患者,保留生育功能手术的术式都是安全有效的,综合评估临床病理因素后,可推荐单侧囊肿剥除术和双侧囊肿剥除术作为首选的治疗方案。对于强烈意愿保留生育功能国际妇产科联盟分期晚的BOT患者,可在充分知情同意的情况下谨慎进行保留生育功能手术,术后尽快尝试妊娠。.
Keywords: fertility-sparing surgery; ovarian borderline tumor; re-fertility; recurrence.